Proof is the key here I believe. There have been so many false dawns and delays in actually getting the product to market that there's a massive "show me" thing going on. Wolgen's approach to communicating plays a massive role too.
But when the log jam breaks - and all the signs are that that will be very soon - then revenues will come on strong. It's the only product for a horrid orphan disease and patients are clamoring for it. Just look at all the petitions floating around about getting widespread delivery up and running and quick!
We're beginning to see the re-rate take place, and when revenues start developing, that will continue apace I believe.
Ann: SCENESSE Treatment in Europe-CUV.AX, page-5
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.84 |
Change
0.260(1.78%) |
Mkt cap ! $741.1M | |||
| Open | High | Low | Value | Volume |
| $14.61 | $14.99 | $14.40 | $1.349M | 91.96K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 644 | $14.79 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.85 | 3489 | 1 |
View Market Depth
| Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
| CUV (ASX) Chart |